|
US8247408B2
(en)
*
|
2005-10-07 |
2012-08-21 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
|
|
CN101395155A
(zh)
*
|
2005-10-07 |
2009-03-25 |
埃克塞里艾克西斯公司 |
PI3Kα的吡啶并嘧啶酮抑制剂
|
|
DK2074122T5
(da)
|
2006-09-15 |
2014-03-17 |
Pfizer Prod Inc |
Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
|
|
EP1914234A1
(en)
*
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
|
JP2010509265A
(ja)
*
|
2006-11-09 |
2010-03-25 |
エフ.ホフマン−ラ ロシュ アーゲー |
キナーゼ阻害剤としての置換6−フェニル−ピリド[2,3−d]ピリミジン−7−オン誘導体及びそれの使用方法
|
|
JP2010523670A
(ja)
*
|
2007-04-10 |
2010-07-15 |
エクセリクシス, インク. |
Pi3kアルファのピリドピリミジノン阻害剤を使用した治療方法
|
|
BRPI0821209A2
(pt)
*
|
2007-12-19 |
2019-09-24 |
Amgen Inc |
composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
|
|
US8389533B2
(en)
*
|
2008-04-07 |
2013-03-05 |
Amgen Inc. |
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
|
|
WO2010039740A1
(en)
|
2008-09-30 |
2010-04-08 |
Exelixis, Inc. |
PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
|
|
WO2010071846A2
(en)
*
|
2008-12-19 |
2010-06-24 |
Afraxis, Inc. |
Compounds for treating neuropsychiatric conditions
|
|
JP2013507395A
(ja)
|
2009-10-09 |
2013-03-04 |
アフラクシス・インコーポレイテッド |
Cns障害治療用の8−エチル−6−(アリール)ピリド[2,3−d]ピリミジン−7(8h)−オン
|
|
US8889696B2
(en)
|
2009-12-18 |
2014-11-18 |
Temple University—Of the Commonwealth System of Higher Education |
Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
|
|
UY33221A
(es)
|
2010-02-09 |
2011-09-30 |
Univ California |
MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
|
|
US8680099B2
(en)
*
|
2010-06-10 |
2014-03-25 |
Afraxis Holdings, Inc. |
6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
|
|
CA2807498C
(en)
|
2010-08-05 |
2017-02-07 |
Temple University-Of The Commonwealth System Of Higher Education |
2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
CN103703000B
(zh)
|
2011-03-23 |
2015-11-25 |
安姆根有限公司 |
Cdk4/6和flt3的稠合三环双重抑制剂
|
|
ES2704744T3
(es)
|
2012-06-13 |
2019-03-19 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
EA035095B1
(ru)
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
|
KR20170032244A
(ko)
|
2014-07-26 |
2017-03-22 |
선샤인 레이크 파르마 컴퍼니 리미티드 |
Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
MX373169B
(es)
|
2015-02-20 |
2020-04-24 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
CN109803968A
(zh)
|
2016-08-15 |
2019-05-24 |
辉瑞公司 |
吡啶并嘧啶酮cdk2/4/6抑制剂
|
|
CN108191857B
(zh)
*
|
2017-01-24 |
2020-10-23 |
晟科药业(江苏)有限公司 |
6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
CN111032655B
(zh)
*
|
2017-08-31 |
2022-09-02 |
达纳-法伯癌症研究所股份有限公司 |
Egfr和/或her2抑制剂和使用方法
|
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
WO2020006210A1
(en)
*
|
2018-06-27 |
2020-01-02 |
Tufts Medical Center, Inc. |
Pyridopyrimidine compounds and methods of their use
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TW202115024A
(zh)
|
2019-08-14 |
2021-04-16 |
美商英塞特公司 |
作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
AU2020364007A1
(en)
*
|
2019-10-11 |
2022-04-28 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含fgfr抑制劑及nectin-4靶向劑之組合療法
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
CN117430597A
(zh)
*
|
2022-07-14 |
2024-01-23 |
浙江同源康医药股份有限公司 |
用作cdk4激酶抑制剂的化合物及其应用
|
|
WO2026024674A1
(en)
|
2024-07-22 |
2026-01-29 |
Genesis Therapeutics, Inc. |
Methods of treating skp2-associated cancers
|